AU2001288061A1 - Drug resistance-associated gene and use thereof - Google Patents

Drug resistance-associated gene and use thereof

Info

Publication number
AU2001288061A1
AU2001288061A1 AU2001288061A AU8806101A AU2001288061A1 AU 2001288061 A1 AU2001288061 A1 AU 2001288061A1 AU 2001288061 A AU2001288061 A AU 2001288061A AU 8806101 A AU8806101 A AU 8806101A AU 2001288061 A1 AU2001288061 A1 AU 2001288061A1
Authority
AU
Australia
Prior art keywords
drug resistance
associated gene
gene
drug
resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001288061A
Other languages
English (en)
Inventor
Yoshikazu Hara
Hideya Komatani
Hidehito Kotani
Rinako Nakagawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD KK
Original Assignee
Banyu Phamaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Phamaceutical Co Ltd filed Critical Banyu Phamaceutical Co Ltd
Publication of AU2001288061A1 publication Critical patent/AU2001288061A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001288061A 2000-10-03 2001-09-18 Drug resistance-associated gene and use thereof Abandoned AU2001288061A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-303441 2000-10-03
JP2000303441 2000-10-03
PCT/JP2001/008112 WO2002028894A1 (fr) 2000-10-03 2001-09-18 Gene se rapportant a la tolerance aux medicaments et utilisation associee

Publications (1)

Publication Number Publication Date
AU2001288061A1 true AU2001288061A1 (en) 2002-04-15

Family

ID=18784642

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001288061A Abandoned AU2001288061A1 (en) 2000-10-03 2001-09-18 Drug resistance-associated gene and use thereof

Country Status (6)

Country Link
US (2) US20030232362A1 (fr)
EP (1) EP1323735A4 (fr)
JP (1) JPWO2002028894A1 (fr)
AU (1) AU2001288061A1 (fr)
CA (1) CA2426621A1 (fr)
WO (1) WO2002028894A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1054894B2 (fr) 1998-02-05 2016-11-09 University of Maryland Baltimore Proteine de resistance aux medicaments contre le cancer du sein (bcrp) et adn codant cette proteine
HU0100947D0 (en) * 2001-03-02 2001-05-28 Solvo Kft Screening system based on expression of abcg2 half transporter protein in an expression system free of other abc-transporters, abcg2 homodimers
US20060057579A1 (en) * 2002-06-17 2006-03-16 Banyu Pharmaceutical Co., Ltd., Method for predicting a drug transport capability by abcg2 polymorphisms
JPWO2005078100A1 (ja) * 2004-02-13 2007-08-30 稲澤　譲治 薬剤耐性を獲得した癌細胞の検出方法
JP2007528730A (ja) * 2004-03-12 2007-10-18 ザ クイーンズ ユニヴァーシティ オブ ベルファスト 治療および測定法
US20090081645A1 (en) * 2004-08-02 2009-03-26 Hidehito Kotani Method of assuming drug sensitivity to cdk4 inhibitor
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
US9241994B2 (en) 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
EP2356248A4 (fr) * 2008-11-12 2012-06-20 Univ Johns Hopkins Essai de criblage à base d' imagerie par bioluminescence et inhibiteurs de abcg2
JP5817038B2 (ja) * 2009-06-22 2015-11-18 洋孝 松尾 尿酸トランスポーター、並びに、尿酸輸送関連疾患素因及び炎症関連疾患素因の評価方法及び評価キット、検査体及び薬
JP5190477B2 (ja) * 2010-02-22 2013-04-24 譲治 稲澤 カンプトテシン類の制癌剤に対する薬剤耐性を獲得した肺癌細胞の検出方法
US10094017B2 (en) 2015-01-29 2018-10-09 Slt Technologies, Inc. Method and system for preparing polycrystalline group III metal nitride
CN106432490B (zh) * 2016-09-14 2020-01-07 北京大学 一种abcg2单克隆抗体及其用途
CN110627855B (zh) * 2019-09-12 2022-06-17 南京大学 龙纳霉素及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341936A (en) * 1979-12-17 1982-07-27 Virgin George C Electromagnetic induction energy converter
US6008482A (en) * 1994-10-24 1999-12-28 Matsushita Electric Industrial Co., Ltd. Microwave oven with induction steam generating apparatus
JPH08264272A (ja) * 1995-03-27 1996-10-11 Seta Giken:Kk 電磁誘導加熱装置
WO1998055614A2 (fr) * 1997-06-04 1998-12-10 Genetics Institute, Inc. Proteines secretees et polynucleotides codant ces proteines
EP1054894B2 (fr) * 1998-02-05 2016-11-09 University of Maryland Baltimore Proteine de resistance aux medicaments contre le cancer du sein (bcrp) et adn codant cette proteine
US20050048610A1 (en) * 1999-06-17 2005-03-03 Incyte Corporation Human transport proteins

Also Published As

Publication number Publication date
JPWO2002028894A1 (ja) 2004-06-03
WO2002028894A1 (fr) 2002-04-11
EP1323735A1 (fr) 2003-07-02
EP1323735A4 (fr) 2005-02-09
US20030232362A1 (en) 2003-12-18
US20070141619A1 (en) 2007-06-21
CA2426621A1 (fr) 2003-04-01

Similar Documents

Publication Publication Date Title
AU2002341959A1 (en) Drug delivery devices and methods
AU2002241538A1 (en) Intrasvascular drug delivery device and use therefor
AU2001231091A1 (en) Identification of genetic components of drug response
AU2001277741A1 (en) 2-aminopyridine compounds and use thereof as drugs
AU2001288061A1 (en) Drug resistance-associated gene and use thereof
HUP0300334A3 (en) Pharmaceutical preparations and their manufacture
AU3072500A (en) Rhamnosyl-transferase gene and uses thereof
AU2002365188A1 (en) Nucleic acid delivery and expression
AU2001227084A1 (en) N-arylhydrazide compounds and use thereof as drugs
AU2002219249A1 (en) Enteric-coated drug formulations and their manufacture
AU2001232244A1 (en) Drug comprising combination
AU2001264488A1 (en) Gene expression cassette and its use
AU2400401A (en) Novel phosphodiesterases and genes thereof
AU1894601A (en) Novel gene and use thereof
AU2001268053A1 (en) Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
AUPR548601A0 (en) Pyrazolopyrazinecompound and pharmaceutical use thereof
AU2002233285A1 (en) Interleukin-1 related gene and protein
AU2001262699A1 (en) Biologically active agents and drugs
AU2001262928A1 (en) Pharmaceutical compositions and their use
AU2001228784A1 (en) Inositol derivatives and their pharmaceutical use
AU2001249660A1 (en) Cross-incompatibility traits from teosinte and their use in corn
AU7684000A (en) Interferon complex and medicinal use thereof
AU2002240921A1 (en) Medane genes and proteins
AU2406901A (en) Method for expressing gene and use thereof
AU2001266189A1 (en) Materials and methods relating to gene delivery

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application